
Gonorrhoea treatment could combat resistant infections
Newly published Phase III trial results suggest the new antibiotic gepotidacin could treat uncomplicated urogenital gonorrhoea (GC). The trial showed that gepotidacin was non-inferior with 92.6% success rates when compared to 91.2% success rates for intramuscular ceftriaxone plus oral azithromycin combined therapy, a leading combination treatment… Read More
